PMID- 28396095 OWN - NLM STAT- MEDLINE DCOM- 20180319 LR - 20180423 IS - 2152-2669 (Electronic) IS - 2152-2669 (Linking) VI - 17 IP - 6 DP - 2017 Jun TI - Elderly Patients With Chronic Myeloid Leukemia Benefit From a Dasatinib Dose as Low as 20 mg. PG - 370-374 LID - S2152-2650(17)30014-9 [pii] LID - 10.1016/j.clml.2017.02.023 [doi] AB - BACKGROUND: The clinical outcomes of patients with chronic myeloid leukemia (CML) treated with BCR-ABL tyrosine kinase inhibitors has improved markedly; however, the occurrence of adverse events (AEs) means that elderly patients often cannot be administered the standard dose. Nevertheless, some patients treated with low doses of tyrosine kinase inhibitor have achieved good molecular responses. PATIENTS AND METHODS: We retrospectively analyzed the efficacy and safety of low-dose dasatinib treatment of elderly CML patients. The study enrolled 21 patients with newly diagnosed, imatinib-resistant, or imatinib-intolerant chronic phase CML. All the patients were aged >/= 65 years and received dasatinib at a dose of < 100 mg/day. Of these 21 patients, 77% had newly diagnosed CML. RESULTS: Overall, 91% and 72% of patients received a mean dasatinib dose of 3 log reduction in the number of leukemic cells), MR(4), and MR(4.5) were achieved in 96%, 77%, and 62% of the patients, respectively. Of the 15 patients who received a mean dose of